Rep. Debbie Wasserman Schultz Purchases Shares of Baxter International Inc. (NYSE:BAX)

Representative Debbie Wasserman Schultz (D-Florida) recently bought shares of Baxter International Inc. (NYSE:BAX). In a filing disclosed on November 20th, the Representative disclosed that they had bought between $1,001 and $15,000 in Baxter International stock on November 18th.

Representative Debbie Wasserman Schultz also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of New Gold (NYSE:NGD) on 11/18/2024.
• Purchased $1,001 – $15,000 in shares of Patterson-UTI Energy (NASDAQ:PTEN) on 10/23/2024.
• Purchased $1,001 – $15,000 in shares of Viasat (NASDAQ:VSAT) on 10/23/2024.

Baxter International Price Performance

Shares of NYSE BAX opened at $33.12 on Friday. Baxter International Inc. has a 1-year low of $31.60 and a 1-year high of $44.01. The business has a 50-day moving average of $36.34 and a 200-day moving average of $35.69. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.43 and a quick ratio of 1.09. The company has a market capitalization of $16.91 billion, a price-to-earnings ratio of 165.61, a PEG ratio of 12.91 and a beta of 0.60.

Baxter International (NYSE:BAX) last issued its earnings results on Friday, November 8th. The medical instruments supplier reported $0.80 EPS for the quarter, topping the consensus estimate of $0.78 by $0.02. The company had revenue of $3.85 billion during the quarter, compared to analyst estimates of $3.85 billion. Baxter International had a return on equity of 18.30% and a net margin of 0.77%. The business’s revenue was up 3.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.68 EPS. On average, equities analysts anticipate that Baxter International Inc. will post 1.98 EPS for the current fiscal year.

Baxter International Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 2nd. Investors of record on Friday, November 29th will be paid a $0.17 dividend. The ex-dividend date of this dividend is Friday, November 29th. This represents a $0.68 annualized dividend and a yield of 2.05%. Baxter International’s payout ratio is currently 580.03%.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on BAX shares. StockNews.com downgraded Baxter International from a “buy” rating to a “hold” rating in a report on Monday, November 11th. JPMorgan Chase & Co. lowered their price target on Baxter International from $44.00 to $42.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. Stifel Nicolaus reduced their price objective on Baxter International from $46.00 to $38.00 and set a “buy” rating for the company in a research report on Monday, November 11th. Citigroup lifted their price objective on Baxter International from $38.00 to $40.00 and gave the company a “neutral” rating in a research report on Tuesday, October 1st. Finally, The Goldman Sachs Group lifted their price objective on Baxter International from $36.00 to $40.00 and gave the company a “neutral” rating in a research report on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $40.91.

Hedge Funds Weigh In On Baxter International

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. First PREMIER Bank purchased a new position in Baxter International during the 3rd quarter valued at about $25,000. Innealta Capital LLC bought a new stake in shares of Baxter International in the 2nd quarter valued at about $27,000. Fortitude Family Office LLC bought a new stake in shares of Baxter International in the 3rd quarter valued at about $38,000. LRI Investments LLC acquired a new stake in Baxter International in the 1st quarter worth approximately $39,000. Finally, Versant Capital Management Inc boosted its stake in Baxter International by 974.2% in the 2nd quarter. Versant Capital Management Inc now owns 1,332 shares of the medical instruments supplier’s stock worth $45,000 after purchasing an additional 1,208 shares in the last quarter. Institutional investors own 90.19% of the company’s stock.

About Representative Wasserman Schultz

Debbie Wasserman Schultz (Democratic Party) is a member of the U.S. House, representing Florida’s 25th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2025. Wasserman Schultz (Democratic Party) is running for re-election to the U.S. House to represent Florida’s 25th Congressional District. She declared candidacy for the Democratic primary scheduled on August 20, 2024. Wasserman Schultz was first elected to the U.S. House in 2004 from District 20. She previously represented District 34 of the Florida State Senate from 2003 to 2004, District 32 of the Florida State Senate from 2001 to 2003, and District 97 of the Florida House of Representatives from 1993 to 2001. She served as one of the Chief Deputy Whips of the Democratic caucus for the 113th Congress. She also served as the chair of the Democratic National Committee. On July 24, 2016, Wasserman Schultz announced that she would resign her leadership position at the end of the party’s convention. Wasserman Schultz was considered a possible candidate in 2016 for U.S. Senate. However, she announced on March 17, 2015, that she would not seek the Senate seat and would instead run for re-election to the House. Debbie Wasserman Schultz was born in Forest Hills, New York. Wasserman Schultz graduated from Half Hollow Hills High School East in 1984. She earned a B.A. and M.A. from the University of Florida in 1988 and 1990, respectively. Wasserman Schultz’s career experience includes working as a staffer to former U.S. Representative Peter Deutsch.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.